Background: Opioid prescribing has increased over the past two decades in Australia and has been associated with a rise in opioidrelated harm, including hospitalisations. Guidelines for supplying opioids at discharge from hospitals may reduce these associated risks. Examples of these guidelines exist worldwide, but it is unknown what strategies Victorian hospitals are using. Aim: The aim of the present study was to discover what strategies, if any, Victorian hospitals are using to decrease risk associated with opioids prescribed on discharge and the perceived barriers to implementing these strategies. Methods: An online survey was sent to each Victorian hospital. Participants were asked questions about whether their service was using an opioid discharge guideline, the barriers to using these guidelines and whether they would use industry-or peer-developed guidelines if available. Results: Staff from 41 (19.62%) hospitals responded to the survey. Ten hospitals reported having a guideline. Nearly half (41.5%) of the hospitals that did not have a guideline reported that they would consider using an industry-or peer-developed guideline. Time, funding, collaboration between stakeholders and staffing inconsistencies were reported as barriers to development and implementation. Conclusion: Only a small number of Victorian hospitals are using opioid discharge prescribing guidelines. Development of industryor peer-developed guidelines may bypass many of the barriers to development and implementation.
INTRODUCTION
Opioid analgesics are among the highest-risk medications used in clinical practice. Their use in chronic pain has increased markedly in the past 10 years. This increased use has come at a cost to society, with increased non-medical use, serious adverse events, iatrogenic dependence, diversion, overdose and death. 1 Due to the potential harms of these medications, there is a strong case for active regulation and monitoring of these medications at every level of supply. Opioid analgesics are used in many clinical settings to relieve moderate to severe acute pain and chronic pain associated with malignancy. The number of opioid preparations available, and hence the number of opioid prescriptions dispensed, has increased significantly over the past two decades. From 1992 to 2007, there was a 192% increase in Pharmaceutical Benefits Scheme (PBS) prescriptions written for opioid analgesics in Australia. 2, 3 In 2014, this had increased almost fourfold to over 13 million prescriptions. 4 As this supply of opioids to the public has increased, there has been a parallel increase in the number of opioid overdose deaths. 5 Victorian 2016 coronial data identified that pharmaceutical opioids contributed to 183 drug overdose deaths, only slightly fewer than the number of heroinrelated deaths (190). 6 Numerous factors have been reported as possible contributors to the escalation in prescribing rates, including the increase in PBS listings, prescriber or patient preference for specific opioids, the ageing population, expectations of pain relief by pain sufferers, reliance on conventional medications, an increase in treatments (potentially painful) increasing survival rates and an increase in the prevalence of chronic pain and/or reduced availability of illicit drugs. 4, 7 Although the total number of opioid-related hospitalisations in Australia has remained relatively stable, pharmaceutical opioid analgesics have been implicated in an increasing number of presentations and admissions, surpassing heroin and methadone. 7 There are significant risks associated with continued opioid use after discharge from hospital, including ongoing chronic opioid use, respiratory depression, dependence, overdose and even death. Emerging evidence indicates that the initial opioid prescribing patterns determine the risk that a patient will transition to prolonged opioid treatment for chronic non-cancer pain. 8 This increase in risk of prolonged treatment increases as the length of the prescription quantity exceeds 5 day's supply. 9 Transition between different levels of care presents potential for a high risk of medical errors, especially during transition from hospital to primary care. A study of medication error in seven countries found that poor coordination of care was a key factor in these errors. 10 Lack of thorough review at discharge presents a risk that patients will continue on unnecessary medicines, including pain medications, for prolonged periods of time. 11 One of the biggest risks of opioids being prescribed on discharge is that unused and leftover medication may get out into the community, increasing the risks of harm and other unintentional consequences. A 2017 systematic review found a proportion of opioids supplied after surgery were left over, not stored securely and retained instead of appropriately disposed of. These leftover opioids may be an important contributing factor to the non-medical use of these products leading to injury or even death. 12 Further risks include excessive doses or use in combination with other central nervous system depressants, including alcohol and benzodiazepines, which increases the risk of sedation, respiratory depression and overdose. Clear communication between the hospital, patient and primary care is reported as essential for risk reduction. 1 To reduce risk, several strategies have been implemented in Australia and internationally. A 2014 Victorian Department of Health and Human Services survey found that some Victorian health services are using strategies to reduce opioid-associated risks. These strategies related to limiting quantities supplied, the use of opioid risk screening tools, patient education and communication with the patient's general practitioner (GP), but the survey did not gather information on whether the use of opioid discharge guidelines was mandated if available at the health service (H. Lowry, pers. comm., 2016). South Australia's Department for Health and Ageing developed a Clinical Guideline for Prescribing Opioids on Discharge in late 2013. 13 These guidelines had recommendations pertaining to the appropriateness to prescribe opioids on discharge, the quantity of opioids to be prescribed, patient education and communication with the primary care provider. 13 Although these guidelines offer pragmatic recommendations to decrease opioid associated risks, adherence by prescribers and the effectiveness of the guidelines in reducing opioidassociated risks remains unreported. Currently there are no Australian or Victorian guidelines regulating the prescribing of opioids upon discharge from hospital. The adoption of antibiotic stewardship has successfully addressed the problem of emerging antibiotic overprescribing; 14 therefore, there may be a role for a similar program involving pharmacists in opioid prescribing, particularly in the transition of opioid analgesic management from the hospital to the primary care setting. 15 The use and contents of hospital-developed opioid discharge guidelines in Victorian hospitals is not well understood. The barriers to the implementation and use of opioid discharge guidelines for decreasing opioid-associated risk at discharge have not been systematically explored. 16 This knowledge gap formed the focus of the present study.
The aim of the present study was to examine the current practice of Victorian hospitals to decrease risk associated with opioids prescribed on discharge, and to increase understanding of the perceived barriers to the implementation of and adherence to opioid discharge guidelines. The online survey was developed using Qualtrics survey software (Qualtrics, LLC, Provo, UT, USA). Questions were formulated based on work done by the Victorian Department of Health and Human Services and the current literature. 18 The survey (Appendix 1) collected descriptive hospital information, including hospital size, location (rural/regional or metropolitan), whether privately or publicly funded and whether the service had a pharmacy department, as well as the respondent's role at the hospital. Additional information sought included whether the hospital was using a guideline for opioid prescribing at discharge, whether the hospital would consider using an industry-or peerdeveloped guideline and perceived barriers to the implementation and use of a guideline. An industry-or peerdeveloped guideline is defined as a guideline developed by health professionals with a speciality in pain and dependence, and endorsed for use by relevant professional bodies and government departments. The survey was tested using a series of cognitive interviews. The cognitive interviews were conducted in two rounds, with hospital pharmacists and a registered nurse. A number of small changes was made to the survey after each round of interviews. Cognitive interviews involve using probes (both anticipatory and reactive) while a participant is completing the survey to understand what the participant understands each question to be asking. 19 This allowed potential problems with the survey to be identified and corrected. Survey data were entered into a data management database (IBM SPSS version 24; International Business Machines Corporation, Armonk, NY, USA) and frequency distributions were generated. Univariate and bivariate comparisons were made using chi-squared or Fisher's exact tests. Predictors of use, contents and adherence to guidelines and the likelihood of the use of an industry-or peer-developed guideline were explored. Analyses were performed using IBM SPSS version 24 and two-sided p < 0.05 was considered significant. Thematic analysis of barriers to the use and implementation of guidelines was also undertaken.
METHODS

RESULTS
Of the 209 surveys distributed, 46 were returned. Five surveys were incomplete and unusable, leaving 41 to be analysed (Table 1) .
There was a 14.2% difference in the response rate of public (27.0%) versus private (12 Of the 41 respondents, 10 (24.4%) indicated that the hospital had a guideline for opioid prescribing at discharge. There were no significant differences in the location, size, type of hospital (public or private) or presence of a pharmacy department and the use of a guideline. Figure 1 shows the strategies included in the guidelines of the 10 hospitals with guidelines for opioid prescribing at discharge.
As indicated in Figure 1 , the most common strategy implemented was to supply the patient with written and verbal information about their opioid medication, with all 10 hospitals including this recommendation in their guidelines. Nine respondents reported that this recommendation is at least 'satisfactorily' adhered to, whereas one respondent reported that the recommendation is 'somewhat satisfactorily' adhered to. Seven hospitals (70%) included recommendations to reduce quantities of opioid medication at discharge and all reported that this recommendation is at least 'somewhat satisfactorily' adhered to. Eight hospitals (80%) made recommendations to supply the patient's GP with information pertaining to the patient's pain management plan. Seven respondents reported that this recommendation is at least 'satisfactorily' adhered to, with one reporting that it was 'somewhat satisfactorily' adhered to. Only four hospitals (40%) made recommendations to use opioid risk screening tools. Three of these respondents reported that this recommendation is at least 'somewhat satisfactorily' adhered to and one respondent reported it was 'poorly' adhered to. There were no significant differences in results between the location, size, type of hospital (public or private) or presence of a pharmacy department and use of any of the four recommendations.
Of the 30 hospitals not using a current written guideline, 17 (41.5%) said they would consider using peer-or industry-developed guidelines if available, 11 (26.8%) said they may consider doing so and one (2.4%) said they would not. There were no significant differences in the location, size, type of hospital (public or private) or presence of a pharmacy department and desire to use peer-or industry-developed guidelines.
Thematic analysis of the free text responses identified key barriers to the implementation and adherence of guidelines. Respondents reported time, funding and resources as major barriers to producing guidelines. Others reported that cooperation and agreement between different stakeholders, such as anaesthetists and physicians, as potential issues. It was also identified that some hospitals had rotating locums and visiting medical officers, which created difficulties reaching consensus with regard to the development of guidelines and adherence to the recommendations. Respondents also reported that there is little awareness and staff education with regard to issues associated with opioid medication supply.
DISCUSSION
The results from the present study highlight varying regulation with regard to the management of opioid medication at discharge from Victorian hospitals. Hospital pharmacists currently engage in a number of activities to improve medication safety, including medication reconciliation. Because opioid analgesics are emerging as a more serious societal threat, there is the potential to develop the pharmacist's role to ensure appropriate and safe prescribing of opioids at discharge, as shown by a recent study conducted in a Victorian metropolitan hospital. 20 The addition of increased pharmacist input and opioid prescribing guidelines could have significant effects on the management of opioids at discharge. The present study investigated four aspects of opioid management at discharge identified by the literature: (1) reducing opioid quantity at discharge; (2) providing the patient's GP with appropriate discharge information; (3) providing the patient with appropriate written and verbal information; and (4) the use of opioid risk screening tools. The results identified that hospitals placed different levels of importance on some aspects, but respondents universally identified that providing the patient with appropriate information was important. The importance of providing written information has been discussed in other research, suggesting that patients want information about their medical conditions, treatments and outcomes and that written information can increase a patient's knowledge. 21 When patients are discharged from hospital with opioids, it is important that they understand the risk that use of these medications brings. It is vital that patients receive information and advice to ensure they take their opioid medication safely after leaving hospital and that expectations around the duration of use and ongoing treatment are managed appropriately. 18 This information should be supplied in both verbal and written form. Patients should be aware of adverse effects, including sedation, constipation and impairment to perform complex tasks such as driving. It is also necessary to discuss the safe storage and disposal of opioid medication to prevent accidental overdose. 18 In addition, information about the dangers of mixing opioid analgesics with other central nervous system depressants, such as alcohol or benzodiazepines, and the signs and symptoms of overdose should be emphasised.
In the present study, 70% of respondents believed that reducing the quantities of opioids prescribed on discharge is appropriate. This reinforces previous findings by Macintyre et al., 18 who recommended limiting the duration of treatment to the expected duration of pain and/or the time it would take the patient to access their primary care practitioner for pain management review. This is pertinent because recent evidence suggests that as the prescription quantity exceeds 5 day's supply, the risk of prolonged opioid use increases. 9 Macintyre et al. 18 also recommended that the dose prescribed on discharge should not exceed the dose required prior to discharge. Dose was not investigated in the present study as a component of the opioid discharge guidelines. Incorporating dose and duration into a guideline may reduce the chance of opioid overdose, as well as reducing the amount of unused opioids remaining in the community along with the risk of inappropriate prolonged opioid use.
Research has shown there is a potential for harm in the transition of care from hospital to a patient's primary care provider. Admission and discharge from hospital have been identified as being associated with a higher risk for the occurrence of an adverse drug reaction, error and/or event. 18, 22 It is important a patient's GP receives timely and detailed communication from the prescribing hospital when the patient is discharged. This communication should include details of the expected duration of opioid pain management, along with dose reduction strategies if appropriate. 18 Respondents in the present study highlighted the importance of ensuring that a patient's GP is informed of their opioid medication and pain management plan, with 80% of respondents indicating that this should be included in guidelines. Inclusion of GP communication into a guideline may produce more consistency in the transition to primary care, and thus improve continuity of care, minimising risks such as dependence or hospitalisations. Identifying patients at high risk of opioid abuse or dependence can help reduce adverse outcomes. 23 Despite this, only four hospitals in the present study reported including this strategy in their guideline. Screening for key indicators in the patient's history, including family history and psychological makeup, can determine whether the patient has an increased risk of developing a dependence to opioids. 23, 24 When identified as high risk, patients should not be denied opioids if they are clinically indicated, but treatment should be monitored and managed so the potential for misuse and harm is minimised. 18 Integrating this tool into a guideline may help reduce the risk of aberrant behaviour. For such a tool to be implemented successfully, it should be used as a universal precaution to assist with risk identification. Further research investigating the use of this tool and its current low uptake may be needed. Respondents reported several barriers to using a guideline for reducing harm associated with opioid medication at discharge. These barriers included gaining consensus from all stakeholders, which is seen as challenging when there are varying specialities, visiting specialists or consultants and inconsistencies between practices. This is confounded when there is little funding, time or resources for the development of such a guideline. Despite this, for optimal patient care and minimal risk, it is important that these barriers are overcome.
Of the 30 respondents who did not use a guideline at their hospital for supplying opioid medication at discharge, all but one felt they would consider using industry-or peer-developed guidelines. The production of such guidelines may bypass many of the barriers mentioned above. Effective, well-adhered to guidelines implemented in hospitals and health services in Victoria may reduce the current harm associated with opioid analgesic use. To ensure improved buy-in and uptake of guidelines and recommendations, they could be developed into a clinical standard and form part of the National Safety and Quality Health Service (NSQHS) Standards (https://www.safetyandquality.gov.au/ourwork/assessment-to-the-nsqhs-standards/resources-toimplement-the-nsqhs-standards/. Accessed October 2016).
There are several limitations to the present study. The response rate (19.6% valid responses) may make it difficult to generalise the findings of the present study. Despite this, there was a good response from a broad cross-section of hospitals, likely representing across-theboard views. The perceived lower response rate may be due to the original distribution of the survey. First, the survey was distributed to all Victorian hospitals, including very small and day procedure hospitals that may not use opioid medication regularly; therefore, these hospitals may not have completed the survey. Second, the survey was sent to all metropolitan hospitals, including hospitals falling under the auspices of larger 'umbrella' organisations that may have been reluctant to complete the survey more than once for their organisation. Missed responses may not have been relevant to the overall outcome, but may show a lower implementation of guidelines than what is actually being practised. In addition, there may have been response bias with those responding having an alternative opinion to those that did not respond. Responses may also be limited by how recently respondents have practiced and their knowledge of what occurs in 'everyday' practice.
In light of the increasing supply of opioid analgesics and parallel increases in serious harm from these medications, there is critical need for stewardship and regulation around the supply of opioids on discharge; this could be achieved, in part, by the development of an industry-or peer-developed guideline for the prescribing of opioid medication at discharge. An example of this strategy is the approach used in the US, namely the Risk Evaluation and Mitigation Strategy for ExtendedRelease and Long-Acting Opioid Analgesics. 25 Manufacturers are required by the US Food and Drug Administration to supply evidence-based information to prescribers and patient or consumer education. 25 The opioid epidemic and aspects that contribute to ongoing continuing opioid supply into the community are public health issues. The present study has identified that few Victorian hospitals responding to the survey appear to have discharge supply guidelines that could have positive effects on public health and reflect positively on institutional governance around medication safety. Before widespread implementation of guidelines occurs, further investigation is required into the effectiveness of currently implemented guidelines and strategies in reducing the harm associated with opioid medication. To find consensus on what is described as 'best practice' for supplying opioid medication on discharge, a Delphi study targeting addiction medicine specialists, pain specialists, hospital pharmacists and other key stake holders may be useful. 
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STUDY AIMS
The aim of this study is to investigate the use of opioid discharge prescribing guidelines/procedures/policies in Victorian Hospitals. If guidelines/procedures/policies have been developed, we aim to explore the barriers, if any, to adopting these into practice. The anticipated benefit of this study is creating greater knowledge of how health services around Victoria are combating the problems associated with opioid analgesics during the discharge process. This will allow for more targeted support to health services.
THE SURVEY
This study incorporates a short survey lasting approximately 10 minutes. The questions relate your health service's management of opioid discharge prescribing. It is preferable that this survey is completed by an individual who has an understanding of how opioid analgesics are used throughout your health service.
DATA COLLECTED
The data will be collected using the online survey tool 'Qualtrics' where your data will remain completely anonymous. The raw data may be kept for up to 5 years on a La Trobe University password protected servers after the completion of the study.
Any questions regarding this project may be directed to any of the investigators located at the top of this Participant Information Statement. There are no disadvantages, penalties or adverse consequences for not participating or for withdrawing from the research. You have the right to withdraw from active participation in this project at any time but due to the anonymous nature of the study once completed data cannot be withdrawn. If you have any complaints or concerns about your participation in the study that the researcher has not been able to answer to your satisfaction, you may contact the Senior Human Ethics Officer, Ethics and Integrity, Research Office, La Trobe University, Victoria, 3086 (P: 03 9479 1443, E: humanethics@latrobe.edu.au). Please quote the application reference number: S1645.
CONSENT
By completion of this survey you agree to the following: I have read and understood the participant information statement and consent, and any questions I have asked have been answered to my satisfaction. I agree to participate in the project, realising that I may withdraw at any time but due to the anonymous nature if the study, once completed data cannot be withdrawn. I agree that research data provided by me or with my permission during the project may be included in a thesis, presented at conferences and published in journals on the condition that neither my name nor any other identifying information is used. 
